(S1 (S (S (S (VP (VBG Targeting) (NP (NN angiogenesis)))) (: :) (NP (NP (NN progress)) (PP (IN with) (NP (NP (NN anti-VEGF) (NN treatment)) (PP (IN with) (NP (JJ large) (NNS molecules))))))) (. .)))
(S1 (S (S (NP (NP (NN Angiogenesis)) (: --) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (NNS hallmarks)) (PP (IN of) (NP (NN cancer)))))) (: --)) (VP (VBZ has) (VP (VBN emerged) (PP (IN as) (NP (NP (DT a) (JJ valid) (JJ therapeutic) (NN target)) (PP (IN in) (NP (NN oncology)))))))) (. .)))
(S1 (S (S (NP (DT The) (NN VEGF) (NN system)) (VP (VBZ represents) (NP (NP (NP (DT a) (JJ key) (NN mediator)) (PP (IN of) (NP (JJ tumor-initiated) (NN angiogenesis)))) (CC and) (NP (NP (DT the) (JJ first) (NN target)) (PP (IN of) (NP (NP (NN antiangiogenesis) (NNS agents)) (VP (VBN introduced) (PP (IN in) (NP (JJ clinical) (NN practice)))))))))) (. .)))
(S1 (S (S (SBAR (IN Although) (S (NP (NN anti-VEGF) (NNS therapies)) (VP (VBP have) (ADVP (RB clearly)) (VP (VBN demonstrated) (NP (NP (JJ antitumor) (NN efficacy)) (PP (IN in) (NP (JJ various) (NNS malignancies)))))))) (, ,) (SBAR (WHADVP (RB especially) (WRB when)) (S (VP (VBN combined) (PP (IN with) (NP (JJ conventional) (JJ cytotoxic) (NN chemotherapy)))))) (, ,) (NP (NP (PRP$ their) (NN mechanism)) (PP (IN of) (NP (NN action)))) (VP (VBZ is) (RB not) (VP (ADVP (RB fully)) (VBN understood)))) (. .)))
(S1 (S (S (NP (DT This) (NN Review)) (VP (VP (MD will) (VP (VB discuss) (NP (NP (DT the) (NN rationale)) (PP (IN for) (S (VP (VBG using) (NP (JJ antiangiogenic) (NNS compounds)))))))) (CC and) (VP (MD will) (VP (VB focus) (PP (IN on) (NP (NP (JJ large) (NNS molecules)) (, ,) (PP (JJ such) (IN as) (NP (NP (NNS antibodies)) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBP target) (NP (DT the) (NN VEGF) (NN system))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Clinical) (NNS data)) (PP (IN on) (NP (NN bevacizumab)))) (VP (VBZ is) (VP (VBN discussed) (PP (IN in) (NP (NN detail)))))) (. .)))
(S1 (S (S (NP (NP (JJ Predictive) (NNS markers)) (PP (IN for) (NP (JJ anti-VEGF) (NNS agents)))) (VP (VBP have) (RB not) (ADVP (RB yet)) (VP (VBN been) (VP (VBN identified))))) (CC and) (S (NP (NP (NP (NNS questions)) (VP (VBG regarding) (NP (NP (DT the) (NN usefulness)) (PP (IN of) (NP (NN bevacizumab))) (PP (IN in) (NP (DT the) (JJ adjuvant) (NN setting)))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (PRP$ its) (JJ continued) (NN use)) (PP (IN beyond) (NP (NN progression))))) (VP (VBP remain) (ADJP (JJ unanswered)) (, ,) (PP (IN in) (NP (NP (NN spite)) (PP (IN of) (NP (NP (JJ negative) (NNS data)) (PP (IN on) (NP (NP (NN bevacizumab)) (PP (IN in) (NP (NP (VBG treating) (NNS patients)) (PP (IN with) (NP (JJ adjuvant) (NN colon) (NN cancer))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Nonetheless)) (, ,) (NP (NN anti-VEGF) (NN therapy)) (VP (VP (VBZ has) (VP (VBN enhanced) (NP (NP (DT the) (NN arsenal)) (PP (IN of) (NP (NN anticancer) (NNS therapies)))))) (CC and) (VP (VBZ has) (VP (VBN provided) (NP (NP (JJ new) (NNS insights)) (PP (IN into) (NP (NP (DT the) (NN biology)) (PP (IN of) (NP (NN malignancy)))))))))) (. .)))
